客服热线:400-901-9800          客服QQ:4009019800          技术答疑   技术支持   质量反馈   人才招聘   联系我们
首页 > 产品中心 > 标记一抗 > 产品信息
Rabbit Anti-PPAR gamma/PE-Cy3 Conjugated antibody (bs-0530R-PE-Cy3)
订购热线:400-901-9800
订购邮箱:sales@bioss.com.cn
订购传真:010-58129612
技术支持:support@bioss.com.cn
说 明 书: 100ul  
100ul/2980.00元
大包装/询价
产品编号 bs-0530R-PE-Cy3
英文名称 Anti-PPAR gamma/PE-Cy3
中文名称 PE-Cy3标记的过氧化酶活化增生受体γ抗体
别    名 CIMT1; HUMPPARG; NR1C3; Nuclear receptor subfamily 1 group C member 3; PAX8/PPARG Fusion Gene; Peroxisome Proliferator Activated Receptor gamma; PPAR gamma; PPARG; PPARG1; PPARG2; PPARG3; CIMT1; GLM1; HUMPPARG; NR1C3; Nuclear receptor subfamily 1 group C member 3; PAX8/PPARG Fusion Gene; Peroxisome proliferator activated nuclear receptor gamma variant 1; Peroxisome proliferator activated receptor gamma 1; Peroxisome Proliferator Activated Receptor gamma; Peroxisome proliferator-activated receptor gamma; PPAR gamma; PPAR-gamma; PPARG_HUMAN; PPAR gamma 1; PPAR gamma 2; PPAR gamma 3; PPAR gamma-1; PPAR gamma-2; PPAR gamma-3.  
规格价格 100ul/2980元 购买        大包装/询价
说 明 书 100ul  
研究领域 免疫学  信号转导  转录调节因子  激酶和磷酸酶  糖尿病  内分泌病  
抗体来源 Rabbit
克隆类型 Polyclonal
交叉反应 Human, Mouse, Rat, Chicken, Pig, Cow, Rabbit, Sheep, 
产品应用 Flow-Cyt=1:50-200 IF=1:50-200 
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 57kDa
性    状 Lyophilized or Liquid
浓    度 1mg/ml
免 疫 原 KLH conjugated synthetic peptide derived from human PPAR Gamma
亚    型 IgG
纯化方法 affinity purified by Protein A
储 存 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
产品介绍 background:
The PPAR gamma antibody mainly is exist in the white fat organization, the fat for the PPAR gamma is born, blood sugar stability, the disease respond, the artery gruel kind hardens to rise the important function with the tumor occurrence of etc. all, but concerning the PPAR gamma to bone of function is a new research heat to order in recent years.A PPAR of many researches report gamma was go together with the body is after activate can the function promote many capable cells divided to increase to living but repress the ossification cell to divide to cause the bone measure the decrease or bone softs toward the fat cell in the marrow, the PPAR gamma promotes the ability and bones that the fat cell divide metabolize closely related, the performance is increasing along with the growth marrow fat content of the age, the ossification cell metabolism the outcome reduce, the different construction PPAR gamma 2 have the important function.

Function:
Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis.

Subunit:
Forms a heterodimer with the retinoic acid receptor RXRA called adipocyte-specific transcription factor ARF6. Interacts with NCOA6 coactivator, leading to a strong increase in transcription of target genes. Interacts with coactivator PPARBP, leading to a mild increase in transcription of target genes. Interacts with FAM120B. Interacts with PRDM16 (By similarity). Interacts with NOCA7 in a ligand-inducible manner. Interacts with NCOA1 LXXLL motifs. Interacts with TGFB1I1. Interacts with DNTTIP2. Interacts with PRMT2.

Subcellular Location:
Nucleus.

Tissue Specificity:
Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.

DISEASE:
Note=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer.
Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.
Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.
Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.

Similarity:
Belongs to the nuclear hormone receptor family. NR1 subfamily.
Contains 1 nuclear receptor DNA-binding domain.

Database links:

Entrez Gene: 5468 Human

Entrez Gene: 19016 Mouse

Entrez Gene: 25664 Rat

SwissProt: P37231 Human

SwissProt: P37238 Mouse

SwissProt: O88275 Rat

Unigene: 162646 Human

Unigene: 3020 Mouse

Unigene: 23443 Rat



Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

类固醇受体(Steroid Receptors)
过氧化物酶体增殖物激活受体γ(PPARγ)主要存在于白色脂肪组织,PPARγ对于脂肪生成、血糖稳定、炎症反应、动脉粥样硬化和肿瘤等的发生都起到重要的作用。主要在脂肪细胞内表达。PPARγ是噻唑烷二酮类药物(TZDs)作用的药靶,又是脂肪细胞分化的重要调节因子。经研究发现,PPARγ在肥胖及胰岛素抵抗的发病机制中具有十分重要的意义,是治疗糖尿病、肥胖等代谢性疾病的重要药靶。
过氧化物酶体增殖物激活受体γ(PPARγ)属Ⅱ型核受体超家族成员,主要在脂肪细胞内表达。PPARγ是噻唑烷二酮类药物(TZDs)作用的药靶,又是脂肪细胞分化的重要调节因子。现有研究(包括一次于美国加州大学进行的研究)发现PPARγ在肥胖及胰岛素抵抗的发病机制中具有十分重要的意义,是治疗糖尿病、肥胖等代谢性疾病的重要药靶。目前,该受体蛋白质水平的筛选模式已经建立,并正在建立该受体的报告基因的细胞水平筛选评价模式。
版权所有 2019-2022 www.bioss.com.cn 北京博奥森生物技术有限公司
通过国际质量管理体系ISO9001:2008 GB/T19001-2008认证    编号:00115Q211807R1M/1100
京ICP备05066980号         京公网安备110107000727号